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Abstract  
Background: Research concerning the link between individual vascular risk factors and 
cognition is plentiful but few studies have investigated the role of global vascular risk. 
We examined the cross-time associations of several vascular risk scores with cognitive 
performance during aging.  
Methods: Using data from the French SU.VI.MAX cohort, we studied a sample of 3,061 
participants. Framingham coronary heart disease, cardiovascular and stroke risk profiles were 
computed using baseline data (1994-1996). Cognitive performance was assessed after a mean 
of 13 years via a battery of six validated instruments. Principal component analysis identified 
scores for verbal memory and working memory.   
Associations between risk profiles (as continuous variables and in quartiles (Q)) and 
subsequent poor performance (defined as poor cognitive score, i.e. <10th percentile) were 
examined via logistic regression (odds ratios, 95% CI).  
Results: All continuous-scale Framingham risk scores assessed at midlife were inversely and 
uniformly associated with subsequent poor global cognitive performance, especially in terms 
of verbal memory. Considering risk score Q, higher quartiles were associated with poorer 
performance in verbal memory: The fully-adjusted odds ratios (95% CI), comparing Q4 
versus Q1, were 2.84 (1.70, 4.75), 2.31 (1.43, 3.73) and 1.77 (1.13, 2.76) for Framingham 
coronary heart disease, cardiovascular and stroke risk profiles, respectively. Similar findings 
were observed when modeling cognitive outcomes as continuous variables using covariance 
analyses. 
Conclusion: This study supports the existence of an inverse cross-time association between 
midlife vascular risk profiles and subsequent poor cognitive performance in memory. Beyond 
their importance as regards vascular risk, such risk scores may help primary prevention efforts 
in identifying and targeting individuals at high risk of cognitive aging.  
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1. Introduction 
Cardiovascular (CV) disease is a major public health challenge in the western world, likely to 
worsen with the increasing prevalence of obesity and type 2 diabetes [1]. Owing to common 
mechanistic pathways, a growing body of evidence supports a role of CV risk factors in 
cognitive decline etiology [2-4].  
Over the past few decades, multicomponent CV risk scores based on the Framingham Risk 
equations and accounting for joint effects have been elaborated in order to predict CV events 
and to characterize CV profiles in a quantitative manner [5]. According to a recent meta-
analysis, interventions using such validated scores to identify high-risk individuals may help 
decrease CV morbidity and mortality risk [6]. 
Recent clinical research using quantitative MRI reported an inverse association between total 
cerebral brain volume ratio and Stoke Risk Profile, while a positive association was observed 
between total cerebral brain volume ratio and cognitive function [7].  
As recently reviewed [8], most of epidemiological studies investigating the link between CV 
risk scores and subsequent cognitive outcomes are cross-sectional [7;9-12] or have considered 
only the Framingham Stroke risk profile (FSRP) [7;9;10;12-16]. To our knowledge, only one 
study compared different Framingham risk profiles in the same population [17]. Furthermore, 
there is a large heterogeneity in the neuropsychological tests employed, which limits the 
possibility to compare the respective studies [8]. Accordingly, researchers have underlined the 
need to summarize individual cognitive scores via multidimensional techniques (principal 
component analysis, PCA; factor analysis) and to use such summary cognitive scores as 
primary outcomes- rather than only investigating performances on specific tests [2]. 
The aims of the present study were to estimate the cross-time association between different 
Framingham risk scores assessed in midlife using accurate data and subsequent poor 
performance in large sample. Accounting for previously reported limitations, we focused on 
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different cognitive domains characterized by summary scores, and we test if the associations 
differed by the risk profile score used accounting for follow-up bias.  
2. Materials and methods 
2.1 Population 
The SU.VI.MAX study (SUpplémentation en VItamines et Minéraux AntioXydants, 1994-
2002) was a randomized, double-blind, placebo-controlled primary prevention trial including 
12,741 individuals for a planned follow-up of 8 years. It tested the efficacy of daily 
nutritional-dose supplementation with antioxidant vitamins and minerals (ascorbic acid, 
vitamin E, β-carotene, selenium, zinc) on the incidence of cancer, CV morbidity and overall 
mortality [18].  
Following the trial phase, participants were invited for an additional follow-up. From the 
initial sample, 6,850 participants were (on a voluntary basis) included in the SU.VI.MAX 2 
observational study (2007-2009), which investigated the impact of nutrition on quality of 
aging [19].  
The SU.VI.MAX and SU.VI.MAX 2 studies were conducted according to the guidelines laid 
down in the Declaration of Helsinki and were approved by the Ethics Committee for Studies 
with Human Participants of Paris-Cochin Hospital (CCPPRB n° 706 and n° 2364, 
respectively) and the Comité National Informatique et Liberté (CNIL n° 334641 and 
n° 907094, respectively). Written informed consent was obtained from all participants. 
2.2 Selection of the sample 
From the 6,850 participants in the SU.VI.MAX 2 study, we excluded women < 45 years at 
baseline (n=1,267) to obtain a similar age range across genders, those with missing 
neuropsychological data (n=1,136), with missing data for Framingham risk profile 
computation (n=891) or with missing covariate data (n=295). The final sample included 3,261 
participants. 
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2.3 Data collection 
In 2007-2009, all participants were invited to undergo a clinical examination and (in a sub-
sample) a neuropsychological evaluation by trained neuropsychologists. Episodic memory 
was evaluated using the RI-48 delayed cued recall test based on a list of 48 words belonging 
to 12 different categories. This test was designed to limit “ceiling effects” encountered in 
some list-learning tests. The total score was the number of words retrieved (maximum score 
of 48) [20]. Lexical-semantic memory was assessed by verbal fluency tasks, including a 
semantic fluency task (naming as many animals as possible), and a phonemic fluency task 
(citing words beginning with the letter P). The total score was the number of correct words 
produced during a 2-min period for each task [21]. Working memory was assessed with the 
forward and backward digit span. Participants were asked to repeat two sequences of digits, 
forwards or backwards. The number of digits increased by one until the participant failed two 
consecutive trials of the same digit span. One point was scored for each correct sequence 
repeated, with a maximum score of 14 points for digit span forward as well as backward. 
Mental flexibility was assessed through the Delis-Kaplan trail-making test (TMT) [22], 
consisting of connecting numbers and letters alternating between the two series. The score 
was the time in seconds needed to complete the task [23]. We thus reverse-coded this score so 
that higher scores would correspond to better performance, and further log-transformed it to 
improve normality. The cognitive test scores were converted into T scores (mean=50, 
SD=10). A composite cognitive score was defined as the mean of the standardized test scores 
[24]. 
Moreover, principal component analysis (PCA) with orthogonal rotation was performed in 
order to yield summary scores accounting for correlations among the cognitive tests as 
previously outlined[19]. Briefly stated, PCA factors are linear combinations of the initial 
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variables (the cognitive test scores in our case) that explain a maximum of the variance-
covariance structure of these initial variables.  
Habitually, PCA-factors are named after those initial variables with which they have the 
strongest correlations. 
The extracted factors as well as the composite cognitive score were rescaled to have an SD of 
10.  
In order to account for multiple comparisons, results were hierarchically interpreted. We 
defined the composite cognitive score and the extracted PCA-factors as our main outcomes, 
and scores on the TMT (reflecting mental flexibility) as secondary outcome. Mental flexibility 
appeared to be of major interest in the context of our study as it presents a key domain of 
executive function, and previous studies argue for a role of the FSRP in subsequent executive 
functioning [7;9;10;13]. 
We defined the extracted PCA-factors as our main outcomes, but also investigated the specific 
association between mental flexibility (measured by the TMT in our study), a key domain of 
executive function and the risk profile scores, as previous studies argue for a role of the FSRP 
in subsequent executive functioning [7;9;10;13]. 
At baseline, information on sex, age, smoking (never, former, current smoker), alcohol use 
(g/day), physical activity (irregular, <1 h walking/day, 1 h walking/day), occupation 
(employees/office work, manual workers, homemakers/unemployed, white collar), education 
(primary, secondary, university level), self-reported medication use and self-reported memory 
troubles [“Do you have any memory complaints?“ (yes/no)] was collected by questionnaires. 
At the first clinical examination (1995-1996), anthropometric measurements were collected.  
Blood pressure (BP) was measured using a standardized procedure with a mercury 
sphygmomanometer. It was taken once from each arm following a 10-min rest. The mean of 
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these two measurements was used for analyses. Blood samples were obtained after a 12-h 
fast, and all biochemical measurements were centralized.  
The following biochemical indicators were measured at baseline: Fasting blood glucose, 
serum triglycerides and serum total cholesterol (Advia 1650 autoanalyzer; Bayer Diagnostics, 
Puteaux, France), as well as serum apolipoprotein B (nephelemetric assay, BNA Behring). 
HDL-cholesterol was calculated from total cholesterol and apolipoprotein B, using Planella’s 
equation and the Friedewald formula [25;26].  
Diabetes mellitus was defined as glucose concentrations ≥ 7 mmol/L or antidiabetic drug use. 
Depressive symptoms were assessed during SU.VI.MAX 2 using the French version of the 
Center for Epidemiologic Studies Depression (CES-D) Scale  [27]. 
2.4 Statistical analysis 
Coronary heart disease (Framingham Coronary Heart Disease Risk Profile, FCHDRP), 
general CV disease (Framingham Cardiovascular Disease Risk Profile, FCVDRP) and stroke 
(FSRP) risk profiles were calculated using the Framingham equation system with 
SU.VI.MAX baseline data (1994-1996) [28]. The Framingham risk scores include baseline 
age, sex, systolic BP, HDL-cholesterol, total cholesterol, smoking (current versus former or 
never), and diabetes with specific weight. Left ventricular hypertrophy was not available in 
our sample, thus this parameter was not accounted for. 
Framingham risk scores aim to predict 10-year probability of developing coronary heart 
disease, stroke and CV disease. Higher scores have been designed to be associated with a 
higher risk of new events.  
Risk scores were divided into quartiles (Q1-Q4) for analysis and standardized continuous scores 
were also computed. 
Included and excluded participants were compared using the chi² test or Wilcoxon rank test, 
as appropriate.  
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Descriptive baseline characteristics are reported as mean SD) or percentages by sex as 
equations are different for men and women. Reported P-values refer to non-parametric 
Wilcoxon test or to the chi² test, as appropriate.  
Logistic regression was used to model the odds ratio (OR) and 95% confidence interval (CI) 
of poor cognitive performance (i.e., scoring 10th percentile on the cognitive assessment 
allowing to use OR as reliable proxy of relative risk) across Framingham risk score Q, using 
the lowest category as reference. P for trend was assessed, using linear contrast tests across 
the categories. OR of poor cognitive performance according to Framingham risk scores 
modeled as continuous variables (after standardization) were also estimated, i.e. for an 
increase of 1 SD of each risk score.  
In the initial model, analyses were adjusted for age and sex. In the second model, analyses 
were adjusted for follow-up time (year), age at neuropsychological examination (year), sex 
and education (primary, secondary and post-secondary).  
In the third set of models, analyses were further adjusted for occupation (employees 
manual workers, homemakers/ unemployed, white collar), intervention group (active group or 
placebo) during the trial phase (1994-2002), baseline alcohol consumption (g/d), baseline 
physical activity (irregular, <1h/day, ≥1 h /day), depressive symptoms (continuous score 
ranging from 0 to 60) concomitant with the cognitive evaluation, and baseline self-reported 
memory troubles (yes/no).  
As an attempt to partly correct for selection bias, analyses were carried out using inverse 
probability weighting [29]. The probability of being included in the study was determined 
using baseline characteristics, including sociodemographic, lifestyle (alcohol, diet, physical 
activity) and health variables as well as interaction terms, among the original cohort after 
removing women younger than 45 years (N=10,090). The C statistic of the final model was 
0.69 and the quality of the model was estimated through published recommendations (P-value 
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of the square of logit of the predicted value added in the model, Hosmer–Lemeshow test, 
absence of zero fitted probability in both included and excluded participants, comparison of 
the sum of the 10% highest weights in included participants to half of the total sum of weight) 
[29]. 
Data were analyzed using the inverse probability of inclusion as the respective weight.  
To compare the predictive values of the different risk scores on cognition, we used the area 
under the receiver operating characteristic curves (AUC) [30]. AUC comparisons were fit 
using the SAS %add_predictive macro.  
Effect modification by gender and antihypertensive treatment was also tested. Sensitivity 
analyses were also performed after excluding participant developing stroke during the follow-
up (N=39). 
In secondary analysis, covariance analyses were used to estimate the difference in mean 
cognitive scores (95% confidence interval, CI) with similar adjustment strategy for composite 
cognitive score, verbal memory score and working memory score.  
All tests of statistical significance were two-sided and the type I error was set at 5%. 
Statistical analyses were performed using SAS software (version 9.3, SAS Institute Inc, Cary, 
NC, USA). 
3. Results 
Among SU.VI.MAX participants > 45y at baseline (N=10,090), subjects excluded from the 
current study were more likely to be women, younger, more often smokers, with lower levels 
of education, less physically active. They also exhibited higher total cholesterol and fasting 
glucose concentration and higher systolic blood pressure. Excluded participants performed 
worse on some cognitive tests, i.e. digit span, and showed higher depressive symptoms 
(Supplemental table 1). 
11 
 
 
Participants were 65.5 (SD=4.6) years old at the neuropsychological evaluation. Mean follow-
up was 13.4 (SD=0.6) years. 
Characteristics of participants by sex are shown in Table 1. Men reported higher education, 
higher alcohol intake, were less likely to report memory troubles at baseline or depressive 
symptoms at follow-up, and were more physically active than were women. They also had 
higher BMI, BP, glycemia, total and LDL-cholesterol and lower HDL-cholesterol at baseline 
than did women. Men were also more often smokers (current and former). They presented 
higher Framingham risk scores overall. 
Two cognitive factors were extracted with PCA, reflecting 61% of the initial variance. The 
first factor had the strongest correlations, i.e. factor loadings, with semantic (0.80) and 
phonemic fluency (0.66) and the RI-48 cued recall test (0.76), and thus primarily reflected 
language and lexical-semantic memory. The second factor had the strongest correlations with 
forward (0.84) and backward (0.84) digit span tasks, and thus primarily reflected working 
memory.  
Associations between Framingham risk profiles (FCHDRP, FCVDRP and FSRP) in Q and 
subsequent poor cognitive impairment are presented in Table 2. 
FCHDRP and FCVDRP were both associated with global cognitive impairment. Moreover, 
while all three Framingham risk profiles (FCHDRP, FCVDRP FSRP Q) were associated with 
poor performance in verbal memory, none of the risk profiles were associated with poor 
performance in working memory. 
Concerning the association of the TMT with the risk profiles, a significant association with 
FCHDRP, FCVDRP and FSRP as standardized continuous scores was observed, with OR 
(95% confidence interval) comparing 4th versus 1st Q of 1.29 (1.12, 1.49), 1.27 (1.11, 1.46) 
and 1.22 (1.08, 1.38), respectively (data not tabulated).  
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No effect modification by gender or antihypertensive treatment was detected. Also, reanalysis 
of our data after removing participants developing stroke (N=39) provides similar findings. 
Associations between Framingham risk profiles (FCHDRP, FCVDRP and FSRP) - as 
modeled on a continuous standardized scale - and subsequent poor performance are presented 
in Figure 1. 
Considering these continuous-scale standardized risk scores, all three risk profiles were 
significantly and negatively associated with global cognitive impairment and most 
specifically with poor performance in verbal memory, even after adjustment for confounders.  
AUC analysis (supplemental Table 1) revealed no differences in the prediction of poor 
cognitive performance according to risk score (All P >0.05).  
Findings from the secondary analysis testing for the associations between Framingham risk 
profiles (FCHDRP, FCVDRP and FSRP) in Q and subsequent poor cognitive performances 
are presented in Table 3. Findings were similar to those of the primary analysis. All the 
Framingham risk profiles (FCHDRP, FCVDRP and FSRP) were negatively associated with 
verbal memory performances. 
4. Discussion 
Using a large sample of aging adults, this study showed a significant long-term role of all 
three Framingham CV midlife risk profiles in poor cognitive performance during aging, 
particularly in the domain of verbal memory. These findings persisted after accounting for 
many confounders, especially non-modifiable risk factors such as sex and age. Computing of 
area under the ROC curve argue for interchangeability of midlife risk scores in relationship 
with subsequent cognitive function. 
Such scores, easily computable from non-invasive data, are great interest in clinical practice 
to identify very early population at elevated risk in poor cognitive performance in aging. 
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Besides, improvement of modifiable factors may help in maintaining cognitive performance 
in aging. 
For comparison purposes, we modeled these three scores, reflecting heart disease, CV disease 
and stroke risk, as continuous variables. These scores were similarly associated with poor 
performance in the verbal memory domain. However, stroke risk, when modeled in Q, was 
less strongly associated with cognitive impairment than were the other two risk scores, which 
could be partly explained by the fact that stroke risk in our population was low, with small 
variability. 
Only one study reported association between heart disease risk profile (FCHDRP) and 
cognitive outcome [31], especially with verbal fluency and recall what is concordant with our 
findings but only in women. As expected, findings related to FCVDRP and FCHDRP were 
very similar given the strong correlation between these two scores (Spearman r = 0.98). 
A large body of literature argues for a role of vascular risk factors in cognitive health [2-4], 
especially executive function, regulated by the frontal cortex. Next, FSRP does not adequately 
encompass all risk factors. In particular, cholesterol, especially low HDL-cholesterol but also 
total cholesterol, which is not prominent in the FSRP computation, has been associated with 
cognitive dysfunction [2].   
Our findings pertaining to FSRP are in line with previous research [8], albeit scarce, reporting 
a positive association between stroke risk and dysfunction in verbal memory [9;12;17]. In 
contrast, other studies did not detect a harmful impact of higher stroke risk on memory 
performance or decline [7;10;15;32].  
Previous research has documented a role of FSRP in subsequent executive functioning despite 
a marked heterogeneity in the used neuropsychological tests [7;9;10;13]. Such findings are 
consistent with the observed association between FSRP and TMT in our study. 
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Available data pertaining to the role of FCVDRP in cognitive outcomes are more 
heterogeneous, especially concerning the range of investigated cognitive domains, with 
studies focusing on few tests [11] or on global cognitive function only [33]. While Kaffashian 
et al. reported that higher FCVDRP was associated with a more pronounced decline in 
”reasoning” performance in particular [34], Dregan et al. reported a consistent, harmful role 
of higher FCVDRP- irrespective of the cognitive index [17]. 
No prior study investigating the relationship between FSRP and cognitive decline has yet 
compared the different risk scores with respect to the magnitude of their association with 
cognitive performance. Although Kaffashian et al. presented information comparing the 
predictive value of FCVDRP and FSRP against the CAIDE score, which was developed 
specifically to predict dementia, a direct comparison between FCVDRP and FSRP was not 
provided [34]. 
Underlying mechanisms linking vascular risk factors to cognitive aging are numerous. 
Vascular risk factors impair the structure and function of cerebral blood vessels and associated 
cells (neurovascular unit embracing neurons, glia, perivascular, and vascular cells) [35-37]. 
Specifically, impairment in the neurovascular unit may in turn alter regulation of the cerebral 
blood supply, disrupt blood-brain barrier function and the trophic function, as well as reduce 
autoregulation in the brain. Such alterations may also result in brain atrophy and degeneration 
of white matter. Underlying pathways for neurovascular dysfunction may also involve 
oxidative stress and inflammation [35]. 
Several limitations of our study should be stated. First, HDL cholesterol was not measured at 
baseline, but was calculated through validated equations [25;26]. Another limitation pertains to 
the unavailability of left ventricular hypertrophy measures which may have led to 
underestimated risk scores. Another limitation pertains to the evaluation of cognitive 
performance only at follow-up. Thus, we cannot rule out the possibility of pre-existing 
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differences in cognition according to risk profiles, limiting the potential for causal inference, 
and preventing the assessment of cognitive decline. Given the design of our study, caution is 
needed when generalizing the findings, as participants were relatively healthy volunteers 
involved in a long-term nutritional study [38]. An over selection of our sample may also occur 
as participants in the SU.VI.MAX 2 study are those who accepted to pursue the follow-up at 
the end of the SU.VI.MAX study. In turn these participants are also more likely to be health 
conscious. 
Moreover, residual confounding cannot be excluded, despite the extensive adjustment for 
confounders and bias due to non-response or missing data may be an issue in our study but 
has been limited as we used inverse probability weighting. 
In turn, our study also exhibits strengths and other original aspects including its large sample 
of community-dwelling subjects, long follow-up (focusing on midlife exposure) and the use 
of validated and sensitive tools designed to assess various cognitive domains while limiting 
floor/ceiling effects.   
In conclusion, our findings from an initially middle-aged and CV disease-free population 
provide new insights regarding the role of stroke risk profiles but also regarding general CV 
risk profiles in cognition. From a public health viewpoint, these risk scores may also help 
identify and target at-risk individuals, thus strengthening public health efforts aimed at 
cognitive function preservation.  
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Table 1: Baseline characteristics of the sample, SU.VI.MAX study (except when otherwise 107 
specified) 108 
Characteristic Men Women P 
N 1,712 1,549  
Age at cognitive evaluation, y 65.9 (4.6) 65.1 (4.6) <.0001 
Age at baseline, y 52.5 (4.6) 51.7 (4.6) <.0001 
Follow-up, y 13.4 (0.6) 13.4 (0.7) 0.93 
Education,%    
Primary 21.85 20.14 <.0001 
Secondary 35.51 44.67  
Post-secondary 42.64 35.18  
Occupation    <.0001 
Employees 24.72 30.85  
Manual workers 4.11 1.47  
Homemakers/ unemployed 0.28 7.08  
White collar 23.40 8.10  
Physical activity,%   <.0001 
Irregular 21.50 23.43  
<1h/day 25.82 36.28  
≥1 h /day 52.69 40.28  
Smoking status,%    
Non-smokers 37.68 65.78 <.0001 
Former smokers 51.05 25.11  
Current smokers 11.27 9.10  
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Depressive symptoms (CES-D 
score) 
7.3 (6.5) 10.5 (8.1) <.0001 
Self-reported memory troubles,% 27.16 45.00 <.0001 
Alcohol, g/day 24.8 (18.9) 8.5 (9.7) <.0001 
Systolic BP (mm Hg) 128.5 (13.6) 121.6 (13.8) <.0001 
Total cholesterol (mmol/L) 6.1 (1.0) 6.0 (1.0) <.0001 
HDL-cholesterol (mmol/L) 1.7 (0.3) 1.9 (0.3) <.0001 
LDL-cholesterol (mmol/L) 3.9 (0.7) 3.7 (0.7) <.0001 
Fasting glucose (mmol/L) 5.9 (0.7) 5.5 (0.7) <.0001 
Heart disease 10y Framingham 
score (%) 
7.4 (3.7) 3.2 (2.0) <.0001 
CVD 10y Framingham score (%) 11.2 (6.1) 5.1 (3.4) <.0001 
Stroke 10y Framingham score (%) 1.7 (1.1) 0.9 (0.7) <.0001 
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Table 2 Associations between different Framingham risk scores in quartiles (Q) and cognitive 109 
impairment* 110 
Global cognitive 
impairment 
model  Q1 Q2 Q3 Q4 P for 
linear 
trend 
FCHDRP model 0 ref 1.21 (0.83, 1.77) 1.20 (0.78, 1.85) 1.46 (0.89, 2.39) 0.17 
 model 1† ref 1.24 (0.85, 1.83) 1.23 (0.79, 1.91) 1.54 (0.93, 2.55) 0.12 
 model 2‡ ref 1.27 (0.86, 1.87) 1.30 (0.83, 2.04) 1.72 (1.03, 2.87) 0.05 
FCVDRP model 0 ref 1.08 (0.74, 1.59) 1.32 (0.88, 1.98) 1.42 (0.89, 2.27) 0.10 
 model 1† ref 1.15 (0.78, 1.70) 1.39 (0.91, 2.11) 1.53 (0.95, 2.47) 0.06 
 model 2‡ ref 1.19 (0.80, 1.76) 1.46 (0.96, 2.23) 1.66 (1.02, 2.69) 0.03 
FSRP model 0 ref 0.87 (0.59, 1.27) 0.98 (0.66, 1.45) 1.17 (0.76, 1.82) 0.30 
 model 1† ref 0.88 (0.60, 1.29) 0.99 (0.66, 1.49) 1.21 (0.77, 1.88) 0.27 
 model 2‡ ref 0.90 (0.61, 1.33) 1.03 (0.68, 1.55) 1.26 (0.80, 1.98) 0.20 
Verbal memory impairment model  Q1 Q2 Q3 Q4 P for 
linear 
trend 
FCHDRP model 0 ref 1.63 (1.09, 2.44) 2.69 (1.74, 4.14) 2.57 (1.56, 4.22) 0.0001 
 model 1† ref 1.70 (1.13, 2.55) 2.88 (1.85, 4.46) 2.83 (1.71, 4.70) <.0001 
 model 2‡ ref 1.66 (1.10, 2.50) 2.82 (1.81, 4.40) 2.84 (1.70, 4.75) <.0001 
FCVDRP model 0 ref 1.45 (0.98, 2.14) 2.01 (1.33, 3.03) 2.11 (1.32, 3.36) 0.001 
 model 1† ref 1.56 (1.05, 2.32) 2.17 (1.43, 3.30) 2.34 (1.46, 3.77) 0.0004 
 model 2‡ ref 1.56 (1.05, 2.32) 2.12 (1.39, 3.22) 2.31 (1.43, 3.73) 0.001 
FSRP model 0 ref 1.24 (0.86, 1.80) 1.21 (0.81, 1.81) 1.71 (1.11, 2.64) 0.02 
 model 1† ref 1.29 (0.89, 1.88) 1.27 (0.85, 1.91) 1.81 (1.17, 2.82) 0.01 
 model 2‡ ref 1.29 (0.89, 1.89) 1.24 (0.82, 1.87) 1.77 (1.13, 2.76) 0.02 
Working memory 
impairment 
model  Q1 Q2 Q3 Q4 P for 
linear 
trend 
FCHDRP model 0 ref 1.21 (0.86, 1.68) 0.91 (0.60, 1.37) 1.13 (0.71, 1.81) 0.91 
 model 1† ref 1.19 (0.85, 1.67) 0.91 (0.60, 1.37) 1.12 (0.69, 1.80) 0.93 
 model 2‡ ref 1.26 (0.89, 1.77) 1.01 (0.66, 1.54) 1.28 (0.79, 2.07) 0.52 
FCVDRP model 0 ref 1.14 (0.82, 1.59) 0.89 (0.60, 1.30) 1.07 (0.69, 1.67) 0.91 
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 model 1† ref 1.15 (0.83, 1.61) 0.89 (0.60, 1.31) 1.06 (0.68, 1.67) 0.89 
 model 2‡ ref 1.21 (0.86, 1.69) 0.96 (0.65, 1.44) 1.17 (0.74, 1.85) 0.76 
FSRP model 0 ref 1.02 (0.73, 1.42) 0.85 (0.59, 1.24) 1.05 (0.69, 1.59) 0.97 
 model 1† ref 1.00 (0.72, 1.40) 0.83 (0.56, 1.21) 1.01 (0.66, 1.55) 0.84 
 model 2‡ ref 1.05 (0.75, 1.47) 0.89 (0.60, 1.31) 1.09 (0.71, 1.68) 0.88 
FCHDRP: Framingham Coronary Heart Disease Risk Profile 111 
FCVDRP: Framingham Cardiovascular Disease Risk Profile 112 
FSRP:  Framingham Stroke Risk Profile 113 
*Values are adjusted odds ratios of cognitive impairment (95% confidence interval)  114 
**Model 0 is adjusted for age and sex 115 
†Model 1: adjusted for age, sex, education and follow-up time between baseline and cognitive 116 
evaluation 117 
‡Model 2: further adjusted for occupational status, intervention group during the SU.VI.MAX 118 
trial phase (1994-2002), physical activity, alcohol consumption, depressive symptoms, 119 
baseline self-reported memory troubles 120 
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Table 3 Associations between different Framingham risk scores in quartiles (Q) and cognitive 121 
functioning* 122 
Composite cognitive 
score 
model  Q1 Q2 Q3 Q4 P for linear 
trend 
FCHDRP model 0 0.00 (. - . ) -0.01 (-1.03- 1.01) -0.78 (-1.98- 0.43) -0.75 (-2.16- 0.66) 0.20 
 model 1† 0.00 (. - . ) -0.19 (-1.16- 0.78) -1.01 (-2.15- 0.14) -1.12 (-2.47- 0.23) 0.06 
 model 2‡ 0.00 (. - . ) -0.44 (-1.40- 0.52) -1.49 (-2.63- -0.36) -1.73 (-3.07- -0.39) 0.01 
FCVDRP model 0 0.00 (. - . ) -0.30 (-1.31- 0.71) -0.83 (-1.96- 0.30) -0.81 (-2.14- 0.51) 0.17 
 model 1† 0.00 (. - . ) -0.69 (-1.65- 0.26) -1.18 (-2.25- -0.10) -1.27 (-2.53- -0.00) 0.04 
 model 2‡ 0.00 (. - . ) -0.94 (-1.88- 0.01) -1.57 (-2.64- -0.51) -1.71 (-2.96- -0.46) 0.01 
FSRP model 0 0.00 (. - . ) 0.21 (-0.78- 1.21) 0.18 (-0.92- 1.28) -0.48 (-1.75- 0.78) 0.48 
 model 1† 0.00 (. - . ) 0.04 (-0.91- 0.99) -0.08 (-1.13- 0.98) -0.69 (-1.91- 0.52) 0.27 
 model 2‡ 0.00 (. - . ) -0.19 (-1.13- 0.74) -0.43 (-1.48- 0.61) -0.98 (-2.18- 0.23) 0.11 
Verbal Memory model  Q1 Q2 Q3 Q4 P for linear 
trend 
FCHDRP model 0 0.00 (. - . ) -0.37 (-1.39- 0.66) -2.07 (-3.28- -0.86) -2.05 (-3.47- -0.64) 0.001 
 model 1† 0.00 (. - . ) -0.58 (-1.57- 0.41) -2.30 (-3.47- -1.13) -2.45 (-3.83- -1.07) 0.0001 
 
model 2‡ 0.00 (. - . ) -0.70 (-1.69- 0.29) -2.54 (-3.72- -1.37) -2.77 (-4.15- -1.39) <0.0001 
FCVDRP model 0 0.00 (. - . ) -0.30 (-1.32- 0.71) -1.47 (-2.61- -0.34) -1.83 (-3.16- -0.50) 0.002 
 model 1† 0.00 (. - . ) -0.68 (-1.66- 0.29) -1.82 (-2.92- -0.72) -2.29 (-3.59- -1.00) 0.0002 
 
model 2‡ 0.00 (. - . ) -0.82 (-1.80- 0.15) -2.03 (-3.13- -0.92) -2.53 (-3.83- -1.24) <0.0001 
FSRP model 0 0.00 (. - . ) 0.22 (-0.78- 1.23) -0.42 (-1.53- 0.68) -0.93 (-2.21- 0.34) 0.10 
 model 1† 0.00 (. - . ) 0.03 (-0.94- 1.00) -0.74 (-1.81- 0.34) -1.20 (-2.44- 0.04) 0.03 
 
model 2‡ 0.00 (. - . ) -0.11 (-1.08- 0.86) -0.94 (-2.02- 0.14) -1.37 (-2.62- -0.12) 0.02 
Working memory model  Q1 Q2 Q3 Q4 P for linear 
trend 
FCHDRP model 0 0.00 (. - . ) 0.36 (-0.68- 1.39) 1.14 (-0.08- 2.37) 1.13 (-0.30- 2.56) 0.08 
 model 1† 0.00 (. - . ) 0.32 (-0.70- 1.34) 1.07 (-0.14- 2.27) 1.02 (-0.39- 2.44) 0.10 
 
model 2‡ 0.00 (. - . ) 0.09 (-0.92- 1.10) 0.62 (-0.59- 1.82) 0.49 (-0.92- 1.91) 0.39 
FCVDRP model 0 0.00 (. - . ) -0.11 (-1.14- 0.91) 0.44 (-0.71- 1.58) 0.82 (-0.52- 2.16) 0.17 
 model 1† 0.00 (. - . ) -0.28 (-1.28- 0.73) 0.30 (-0.83- 1.43) 0.67 (-0.65- 2.00) 0.23 
 
model 2‡ 0.00 (. - . ) -0.48 (-1.48- 0.51) -0.06 (-1.18- 1.07) 0.29 (-1.03- 1.62) 0.55 
FSRP model 0 0.00 (. - . ) 0.11 (-0.90- 1.12) 0.75 (-0.37- 1.86) 0.36 (-0.92- 1.65) 0.41 
 model 1† 0.00 (. - . ) 0.07 (-0.93- 1.06) 0.72 (-0.38- 1.83) 0.36 (-0.91- 1.63) 0.41 
 
model 2‡ 0.00 (. - . ) -0.12 (-1.11- 0.86) 0.42 (-0.68- 1.52) 0.14 (-1.13- 1.41) 0.65 
FCHDRP: Framingham Coronary Heart Disease Risk Profile 123 
FCVDRP: Framingham Cardiovascular Disease Risk Profile 124 
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FSRP:  Framingham Stroke Risk Profile 125 
*Values are adjusted odds ratios of cognitive impairment (95% confidence interval)  126 
**Model 0 is adjusted for age and sex 127 
†Model 1: adjusted for age, sex, education and follow-up time between baseline and cognitive 128 
evaluation 129 
‡Model 2: further adjusted for occupational status, intervention group during the SU.VI.MAX 130 
trial phase (1994-2002), physical activity, alcohol consumption, depressive symptoms, 131 
baseline self-reported memory troubles 132 
133 
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Supplemental Table 1: Comparison between included and excluded participants for baseline 134 
characteristic and neuropsychologic tests (SU.VI.MAX 2) study, 1994–2007  135 
 Excluded participants Included participants  
variable Values1 N with 
available data 
Values1 N with 
available 
data 
P2 
General characteristics      
Age at baseline, y 51.2 ± 4.6 6829 52.1 ± 4.6 3261 0 
Male, % 50.21 6829 52.5 3261 0.03 
Intervention group, % 48.13 6829 53.73 3261 <.0001 
Education, %  6829  3261 <.0001 
Primary 24.60  21.04   
Secondary 39.87  39.87   
Post-secondary 35.52  39.1   
Physical activity, %  6829  3261 <.0001 
Irregular 29.17  22.42   
< 1 h/day 28.17  30.79   
≥ 1 h/day 42.66  46.8   
Smoking status, %  6829  3261 <.0001 
Never smokers 41.63  51.03   
Former smokers 43.23  38.73   
Current smokers 15.14  10.24   
Alcohol, g/day 20.9 ± 23.1 3769 20.1 ± 20.4 2601 0.31 
Self-reported health quality  6829  3261 <.0001 
 3.54  0.49   
 22.01  26.1   
 59.03  62.13   
 14.56  10.86   
 0.86  0.43   
BMI, kg/m² 23.8 ± 6.2 6829 24.4 ± 3.4 3261 0.44 
Total cholesterol (mmol/L) 6.2 ± 1.1 6519 6.1 ± 1.0 3261 0.0003 
Fasting glucose (mmol/L) 5.8 ± 1.1 6308 5.7 ± 0.7 3261 0.001 
Systolic BP (mm Hg) 126.3 ± 14.6 4041 125.2 ± 14.1 3261  
Cognitive tests      
Forward digit span 6.9 ± 2.0 1266 7.0 ± 2.0 3261 0.03 
Backward digit span 6.2 ± 2.1 1265 6.3 ± 2.1 3261 0.04 
Trail-making test (time in sec) 95.1 ± 40.7 1230 92.6 ± 38.7 3261 0.09 
RI-48 cued-recall task (no. of 
words) 
26.2 ± 6.1 1237 26.3 ± 6.1 3261 0.72 
Phonemic fluency (no. of words) 30.2 ± 16.4 2293 29.8 ± 16.0 3250 0.46 
Semantic fluency (no. of words) 29.3 ± 8.2 1223 29.6 ± 8.1 3261 0.38 
CES-D score 9.7 ± 8.2 2232 8.8 ± 7.5 3261 0.001 
 Abbreviations: CES-D, Center for Epidemiologic Studies–Depression Scale; RI–48, rappel indicé–48 items.  136 
1 Values are mean ± Sd as appropriate, 137 
2 P values were based on Kruskal-Wallis or chi-square-trend tests.  138 
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Supplemental Table 2: Discrimination and calibration analysis for different Framingham risk 139 
profiles 140 
 
Model A 
with 
Model B 
with 
Model C 
with 
Model C Model B Model C 
Stroke risk 
profile 
CHD risk 
profile 
CVD risk 
profile 
versus versus versus 
   
Model A Model A Model B 
Global cognitive impairment 
    
AUC 0.72 0.73 0.73 
   
P for difference in AUC 
  
0.39 0.36 0.49 
P value Hosmer Lemeshow test for 
calibration 
0.23 0.88 0.82 
   
Verbal memory impairment 
      
AUC 0.68 0.68 0.68 
   
P for difference in AUC 
  
0.47 0.68 0.83 
P value Hosmer Lemeshow test for 
calibration 
0.38 0.62 0.34 
   
Working memory impairment 
    
AUC 0.66 0.66 0.66 
   
P for difference in AUC 
  
1.00 0.95 0.88 
P value Hosmer Lemeshow test for 
calibration 
0.26 0.47 0.33 
   
AUC: area under the receiver operating curves  141 
 142 
